Observational Retrospective Multicenter Study to Evaluate Clinical Outcome Variables Change With dapaGLiflozin Treatment Introduced in Patients With T2D uncOntrolled by the Current Therapy in Real Clinical Practice in RussIA
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GLORIA
- Sponsors AstraZeneca
- 12 Jan 2018 Planned End Date changed from 31 Dec 2017 to 30 Sep 2018.
- 12 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 30 Sep 2018.
- 11 Sep 2017 Planned End Date changed from 31 Aug 2017 to 31 Dec 2017.